22%
h the outlook for adding 600 new store additions in fiscal '26. In terms of our network age, around 22% of our stores have been operational for less than 2 years, and the remaining 78% of our stores have
rs,
'26. In terms of our network age, around 22% of our stores have been operational for less than 2 years, and the remaining 78% of our stores have been operational for 2 years or more. In terms of our netwo
78%
etwork age, around 22% of our stores have been operational for less than 2 years, and the remaining 78% of our stores have been operational for 2 years or more. In terms of our network size -- store size
2.6 million
f our network size -- store size, at the end of the quarter, our network grew to 4,930 stores, with 2.6 million plus square feet compared to 4,552 stores and 2.4 million plus square feet at the end of September
2.4 million
r, our network grew to 4,930 stores, with 2.6 million plus square feet compared to 4,552 stores and 2.4 million plus square feet at the end of September '24. The average store size is 528 square feet. An update
21.5%
armaceutical and non-pharmaceutical categories. Private label sales for quarter 2 FY '26 constitute 21.5%, pharma being 12.1% and non-pharma 9.6% as a percentage of our total revenues. MedPlus Health Ser
12.1%
-pharmaceutical categories. Private label sales for quarter 2 FY '26 constitute 21.5%, pharma being 12.1% and non-pharma 9.6% as a percentage of our total revenues. MedPlus Health Services Limited Novemb
9.6%
ories. Private label sales for quarter 2 FY '26 constitute 21.5%, pharma being 12.1% and non-pharma 9.6% as a percentage of our total revenues. MedPlus Health Services Limited November 03, 2025 On GMV
19.8%
3, 2025 On GMV basis, during the current quarter, the share of private label pharma sales stood at 19.8% compared to 7.9% in Q1 FY '24, which was prior to the launch of MedPlus-branded pharmaceutical prod
7.9%
sis, during the current quarter, the share of private label pharma sales stood at 19.8% compared to 7.9% in Q1 FY '24, which was prior to the launch of MedPlus-branded pharmaceutical products. An update o
INR16,793 million
aceutical products. An update on the financial numbers. Our consolidated revenue for the quarter is INR16,793 million. Our consolidated operating EBITDA for the quarter stood at INR887 million, representing 5.3%. Arou
INR887 million
ue for the quarter is INR16,793 million. Our consolidated operating EBITDA for the quarter stood at INR887 million, representing 5.3%. Around 99% of our revenues is from our pharmacy operations. Revenue from pharma